CN203370016U - Posterior eye segment iontophoresis medicine dosing device - Google Patents
Posterior eye segment iontophoresis medicine dosing device Download PDFInfo
- Publication number
- CN203370016U CN203370016U CN201320308035.2U CN201320308035U CN203370016U CN 203370016 U CN203370016 U CN 203370016U CN 201320308035 U CN201320308035 U CN 201320308035U CN 203370016 U CN203370016 U CN 203370016U
- Authority
- CN
- China
- Prior art keywords
- electrode
- active electrode
- posterior segment
- drug delivery
- iontophoresis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title abstract description 22
- 210000003488 posterior eye segment Anatomy 0.000 title 1
- 210000001508 eye Anatomy 0.000 claims abstract description 32
- 210000005252 bulbus oculi Anatomy 0.000 claims abstract description 23
- 238000012377 drug delivery Methods 0.000 claims abstract description 20
- 239000003937 drug carrier Substances 0.000 claims abstract description 17
- 239000002184 metal Substances 0.000 claims abstract description 13
- 210000004087 cornea Anatomy 0.000 claims abstract description 6
- 230000005684 electric field Effects 0.000 claims description 15
- 210000000744 eyelid Anatomy 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 230000002123 temporal effect Effects 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000011810 insulating material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 9
- 210000004204 blood vessel Anatomy 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 210000000795 conjunctiva Anatomy 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 7
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000003786 sclera Anatomy 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000005944 tissue migration Effects 0.000 description 2
- 210000004127 vitreous body Anatomy 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000150100 Margo Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000000103 occipital bone Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
Images
Landscapes
- Electrotherapy Devices (AREA)
Abstract
本实用新型公开了一种眼后段离子电渗给药的装置，能有效增加眼后段给药浓度，并可以在较短的时间内达到更好的治疗效果，而且局部副作用小。一种眼后段离子电渗给药的装置，包括：椭圆形状的第一活性电极，与眼球生理弧度相适应，中间有可以暴露角膜的圆孔，第一活性电极包括三层，最外层为支撑体，中间为导电极片，最内层为药物载体；第二活性电极，由多个金属电极片组成；被动电极，为一个金属电极片；第一活性电极和第二活性电极连接在直流电源上相同的极性上，被动电极连接在另一极性上。第二活性电极与第一活性电极连接在相同的电源电极上，可以抑制结膜血管对药物的分流，从而提高药物的有效利用。
The utility model discloses an iontophoresis drug delivery device for the posterior segment of the eye, which can effectively increase the drug concentration of the posterior segment of the eye, achieve better therapeutic effect in a short period of time, and have less local side effects. A device for iontophoresis drug delivery in the posterior segment of the eye, comprising: a first active electrode in an elliptical shape, adapted to the physiological curvature of the eyeball, with a round hole in the middle that can expose the cornea, the first active electrode includes three layers, the outermost layer It is a support body, the middle is a conductive electrode sheet, and the innermost layer is a drug carrier; the second active electrode is composed of a plurality of metal electrode sheets; the passive electrode is a metal electrode sheet; the first active electrode and the second active electrode are connected on On the same polarity of the DC power supply, the passive electrode is connected on the other polarity. The second active electrode is connected to the same power supply electrode as the first active electrode, which can inhibit the shunting of conjunctival blood vessels to the drug, thereby improving the effective utilization of the drug.
Description
Technical field
This utility model relates to a kind of medical treatment device, particularly the device of a kind of back segment iontophoresis administration.
Background technology
Eye posterior segment drug delivery mode mainly contains following several at present: putting drops in eyes, wall of eyeball is injected (comprising subconjunctival injection, the injection of ball week and retrobulbar injection) outward, intraocular injection, implant and the whole body administration of eye table or ophthalmic, the equal Shortcomings of the whole bag of tricks, for example putting drops in eyes and whole body administration are difficult to reach effective drug level, eyeball injection and place possibility that implant exists local infection, hemorrhage and detachment of retina, and also the wound property operation that has of eye always makes us being difficult to acceptance.And the eye iontophoresis because of it without wound, good effect, be subject to ophthalmology doctors and patients' extensive welcome, iontophoresis is used extensively in medical clinical position, especially at department of dermatologry, rehabilitation department and ophthalmology, its unique advantage is arranged.Iontophoresis produces electric field by two or more electrodes, make active substance (electrically charged medicine) in electric field at two like magnetic poles repel each other, under the effect that there is a natural attraction between the sexes, to the target tissue migration, thereby arrive therapeutic purposes, the iontophoresis technology belongs to the Noninvasive technology, it is easy and simple to handle, curative effect is certain, and patient compliance is high, and clinical practice is extensive.We find under study for action, the ophthalmology iontophoresis is easier to reach drug target concentration during administration in giving cornea and anterior chamber, but eye back segment part is positioned at the augen deep because of vitreous body, choroid and retinal structure, there is the multiple barriers of organizing such as bulbar conjunctiva, sclera, blood retina barrier, the drug level that causes being delivered to a back segment is not high, in this type of disease treatment, how to make medicine effectively arrive at the bottleneck that destination organization is clinical treatment.Still there is no a kind of improved procedure or device to the administration of eye back segment certain orientation.
Summary of the invention
The technical problems to be solved in the utility model is to provide the device of a kind of back segment iontophoresis administration, can effectively increase a posterior segment drug delivery concentration, and can reach in the short period of time better therapeutic effect, and local side effects is little.
In order to solve the problems of the technologies described above, this utility model adopts following technical scheme: the device of a kind of back segment iontophoresis administration, the device of described eye back segment iontophoresis administration comprises: the first active electrode, for ellipse, shape and eyeball physiologic radian adapt, there is the circular hole that can expose cornea centre, described the first active electrode comprises from outside to inside three layers, outermost layer is supporter, the inner surface of supporter is provided with electric conduction electrode-plate, the inner surface of electric conduction electrode-plate is provided with pharmaceutical carrier, electric conduction electrode-plate is connected with the negative or positive electrode of DC source by the first conductive connecting line, the second active electrode, be comprised of a plurality of metal electrode films, and each metal electrode film is connected on the identical polarity that connects the first active electrode on DC source by the second conductive connecting line, Passive electrode, be a metal electrode film, by passive conductive connecting line, is connected on DC source with on the contrary polarity that connects the first active electrode.
It is the electric field shielding assembly that insulant makes that this utility model is provided with a circle at the peripheral surface of described the first active electrode to the human eye direction of bowl.
The upper and lower edge of the first active electrode described in the utility model can be inserted in the conjunctival sac of people's eyeball.
The second active electrode described in the utility model comprises upper eyelid the second active electrode, lower eyelid the second active electrode and temporo side the second active electrode that is crescent shape.
Supporter described in the utility model and electric conduction electrode-plate adopt mechanical embedded structure closely to link together, and described electric conduction electrode-plate is provided with projection, and described supporter is provided with the groove corresponding with described projection, and described projection can embed in groove.
Together with supporter described in the utility model and electric conduction electrode-plate are glutinous.
Have between electric conduction electrode-plate described in the utility model and pharmaceutical carrier and be coated with the conducting medium layer formed, can strengthen the pharmaceutical carrier electric conductivity.
The material of supporter described in the utility model is silica gel; The material of described pharmaceutical carrier is cross-linked hydrogel or gel sponge.
The hole of passing through for the first conductive connecting line is arranged on supporter described in the utility model.
Electric field shielding assembly described in the utility model and described supporter are formed in one.
Compared with prior art, this utility model is provided with the first active electrode and designs by people's eyeball physiologic radian, medicine effectively is delivered in a posterior segment tissues by ionization, the second active electrode is placed in people venous plexus and euangiotic place near the eyes, with the first active electrode, be connected on identical power electrode, can suppress the shunting of conjunctiva blood vessel to medicine, thereby improve effective utilization of medicine, and be provided with the electric field shielding assembly on the first active electrode, by current limit in target area, reduce " the bypass effect " of electric current, improved the targeting of drug delivery, so efficient drug delivery, reduced the time of iontophoresis, make the patient more comfortable, side effect is little.
The accompanying drawing explanation
The front view that Fig. 1 is the first active electrode.
The A-A cutaway view that Fig. 2 is Fig. 1.
The schematic diagram that Fig. 3 is near the second active electrode placement location human eye.
Fig. 4 has illustrated the position that Passive electrode is placed the head part and the annexation of the first active electrode, the second active electrode and Passive electrode and DC source.
The specific embodiment
As shown in Figures 1 to 4, the device of a kind of back segment iontophoresis of this utility model administration, comprise being placed in epibulbar the first active electrode 10 of people, being placed in people upper and lower eyelid and the second active electrode 20 of temporo side, the Passive electrode 30 that is placed in human brain occipital bone tuberosity skin place and the DC source be connected with each electrode near the eyes.Described DC source adopts the configuration that in prior art, the ophthalmology iontophoresis adopts to get final product.
As shown in Figure 1, the first active electrode 10 is oval, there is circular hole 16 that can the exposure angle membrane tissue centre, its integral body is pressed the design of eyeball physiologic radian, according to the human eye conjunctival sac degree of depth (from margo palpebrae to fornix section depths): the about 20mm in upper eyelid, the about 10mm of lower eyelid, the about 28mm(of fissura palpebrae width takes the mean), the about 420mm of conjunctival sac area (comprising the cornea area)
2, eyeball surface amasss about 1520mm
2(pressing diameter 23mm), the upper lower edge of described the first active electrode 10 can be inserted in the conjunctival sac of people's eyeball, make itself and conjunctival sac coincide (except cornea part) as far as possible, the area of such the first active electrode can reach whole eyeball surface long-pending nearly 30%, a high proportion of like this scleral surface is carried out iontophoresis, can make medicine effectively be delivered to a back segment; Simultaneously, according to eyeball face radian, make the first active electrode, guaranteed complete, the close contact of electrode and eyeball, and reduce patient's sense of discomfort.
As shown in Figure 2, the first active electrode 10 is from being divided into three layers outside to inside, outermost layer is supporter 11, and the inner surface of supporter 11 is provided with electric conduction electrode-plate 12, and the inner surface of electric conduction electrode-plate 12 is provided with pharmaceutical carrier 13, porose on supporter 11, can make the first conductive connecting line 14 that connects electric conduction electrode-plate 12 and DC power anode or negative pole pass through, described supporter 11 is by softness, but can keep shape, and the material less to eye irritation made, for example silica gel material.The electric conduction electrode-plate that electric conduction electrode-plate 12 is used for eye electric osmose equipment in prior art, the shape of electric conduction electrode-plate 12 is consistent with body shape, supporter 11 is combined closely with electric conduction electrode-plate 12, can adopt mechanical embedded structure closely to link together: on described electric conduction electrode-plate 12, with supporter 11 opposite sides, to be provided with projection, be provided with the groove corresponding with described projection on described supporter 11, described projection can embed in groove and realize connecting; Together with also can described supporter 11 and electric conduction electrode-plate 12 is glutinous.
Inner surface at electric conduction electrode-plate 12 is provided with pharmaceutical carrier 13, pharmaceutical carrier 13 can adopt cross-linked hydrogel or gel sponge to make, its softness, subexcite, without fibre object or residue, residue in eyeball, and drug target can effectively be adsorbed in pharmaceutical carrier 13, pharmaceutical carrier 13 directly contacts eyeball surface, close contact with assurance with eyeball surface, electric conduction electrode-plate closely is connected with pharmaceutical carrier, for better by drug osmotic in eyeball, be coated with the conducting medium that can strengthen pharmaceutical carrier 13 electric conductivities between described electric conduction electrode-plate 12 and pharmaceutical carrier 13, for example: medical conductive paste.
As shown in Figure 2, being provided with a circle at the peripheral surface of described the first active electrode 10 to the human eye direction of bowl is the electric field shielding assembly 15 that insulant makes, electric field shielding assembly 15 is a kind of current blocking assemblies, its material is insulant, good pliability and low irritant are arranged, for example soft elastic silica gel material.There are some researches show, in attempting to transmit the process of medicine by the sclera iontophoresis, drug level in vitreum does not have the drug level in local blood high, this shows, the driven current conversion of medicine is to " bypass ", from traversing the mobile electric current that flows into perienchyma along eyeball surface that becomes of sclera, medicine is delivered in bypass channel, affected curative effect, electric field shielding assembly 15, can by current limit in target area, reduce " the bypass effect " of electric current, improve the targeting of drug delivery.Vertical tangent plane of electric field shielding assembly 15 can be trapezoidal, subtriangular, oval or other geometries, its bottom contact eyeball surface.Electric field shielding assembly 15 can be connected by mechanical draw-in groove mode with supporter 11, also can connect by the adhesion mode, also can be using both as Integral design.
According to traditional electricity theory, electric current will be minimum along resistance path flow through, in eye iontophoresis process, tear film and conducting medium make CURRENT DISTRIBUTION at whole eyeball surface and enter surrounding tissue, and have nothing to do with the particular location that electric current imports, therefore, in traditional sub-electric osmose process of having hallucinations, electric current can flow into sclera, vitreous body and retina, but also can flow into eyelid and periorbital tissue.Research is found, the bulbar conjunctiva venous return is to affect drug delivery to one of main barrier of eyeball back segment, the venous return main path of conjunctiva is: fornical conjunctiva and most of bulbar conjunctiva are back to the vein of eyelid, circumcorneal venous rete is back to vena ophthalmica, and wherein the eyelid vein is the main path that conjunctiva refluxes.This utility model is provided with the second active electrode 20, by a plurality of metal electrode films, formed, be preferably three metal electrode films, each metal electrode film is connected on identical power electrode with the first active electrode 10 by the second conductive connecting line 24 respectively, three metal electrode films can be positioned over respectively upper and lower eyelid and temporo side skin place's venous plexus and euangiotic place, in order to suppress absorption and the transhipment effect of conjunctiva blood vessel to medicine, reduce the shunting of conjunctiva blood vessel to medicine, improve the drug delivery targeting.As shown in Figure 3, be provided with upper eyelid the second active electrode 21 that is crescent shape in upper eyelid, be provided with lower eyelid the second active electrode 22 that is crescent shape at palpebra inferior, in order to strengthen the electric field action to eyelid vein (being mainly supraorbital vein, angular vein and superficial temporal veins, lacrimal vein); Be provided with temporo side the second active electrode 23 that is crescent shape at temporo side skin place, in order to strengthen the electric field action to periorbital tissue and vena ophthalmica, described the second active electrode 20 directly contacts skin histology, its shape and rest adapt, being not limited to above-mentioned crescent shape, can be subtriangular, oval or other geometries.
This utility model also comprises Passive electrode 30, is a metal electrode film, by passive conductive connecting line 34, is connected on the power electrode contrary with the first active electrode 10.Utilize active substance (electrically charged medicine) in electric field at two like magnetic poles repel each other, under the effect that there is a natural attraction between the sexes, principle to the target tissue migration, the target that the electrically charged drug targeting that Passive electrode 30 discharges as the first active electrode 10 moves, be placed in patient's occipital tuberosity skin place (need cut the skin that hair exposes diameter 1cm).
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201320308035.2U CN203370016U (en) | 2013-05-30 | 2013-05-30 | Posterior eye segment iontophoresis medicine dosing device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201320308035.2U CN203370016U (en) | 2013-05-30 | 2013-05-30 | Posterior eye segment iontophoresis medicine dosing device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203370016U true CN203370016U (en) | 2014-01-01 |
Family
ID=49832574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201320308035.2U Expired - Fee Related CN203370016U (en) | 2013-05-30 | 2013-05-30 | Posterior eye segment iontophoresis medicine dosing device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203370016U (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108670191A (en) * | 2018-06-12 | 2018-10-19 | 中国人民解放军陆军军医大学第附属医院 | Eye electrode |
| KR20180115862A (en) * | 2017-04-14 | 2018-10-24 | 한양대학교 산학협력단 | Method and device for multichannel ocular iontophoresis |
| CN111110439A (en) * | 2020-03-04 | 2020-05-08 | 郑州医笃筑工智能科技有限公司 | Microneedle device for retinal vein |
| CN113413541A (en) * | 2021-06-17 | 2021-09-21 | 中央民族大学 | Eye iontophoresis drug delivery device and method using annular electrode |
-
2013
- 2013-05-30 CN CN201320308035.2U patent/CN203370016U/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180115862A (en) * | 2017-04-14 | 2018-10-24 | 한양대학교 산학협력단 | Method and device for multichannel ocular iontophoresis |
| KR101963021B1 (en) * | 2017-04-14 | 2019-03-27 | 한양대학교 산학협력단 | Method and device for multichannel ocular iontophoresis |
| CN108670191A (en) * | 2018-06-12 | 2018-10-19 | 中国人民解放军陆军军医大学第附属医院 | Eye electrode |
| CN111110439A (en) * | 2020-03-04 | 2020-05-08 | 郑州医笃筑工智能科技有限公司 | Microneedle device for retinal vein |
| CN111110439B (en) * | 2020-03-04 | 2022-01-25 | 郑州医笃筑工智能科技有限公司 | Microneedle device for retinal vein |
| CN113413541A (en) * | 2021-06-17 | 2021-09-21 | 中央民族大学 | Eye iontophoresis drug delivery device and method using annular electrode |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4184275B2 (en) | Device for delivering drugs by transocular electrophoresis | |
| CN103167850B (en) | Device for treating keratoconus by transferring riboflavin through cornea by iontophoresis | |
| US8634907B2 (en) | Intraocular iontophoretic device and associated methods | |
| ES2569334T3 (en) | Eye iontophoresis device that reduces irritation | |
| US11484713B2 (en) | In-ear electrode assembly for non-invasive vagus nerve stimulation | |
| ES2992491T3 (en) | Portable medical device | |
| US20110077582A1 (en) | Intraocular iontophoretic device and associated methods | |
| JP2018517517A (en) | Nasal tear implant for tear production stimulation and related methods | |
| CN203370016U (en) | Posterior eye segment iontophoresis medicine dosing device | |
| US20200085618A1 (en) | Intrascleral drug delivery device and associated methods | |
| WO2012162459A1 (en) | Device and method for administering eye medications | |
| PT1434623E (en) | Device for medicine delivery by intraocular iontophoresis or electroporation | |
| CN209899760U (en) | Atomizing hot compress integral type physiotherapy eye-shade | |
| CN203389001U (en) | Posterior eye segment transscleral controlled-release administration apparatus | |
| US8755880B2 (en) | Intraocular iontophoretic device and associated methods | |
| KR20200051924A (en) | Smart contact lens for non-invasive drug delivery | |
| JP2004528871A (en) | Ocular iontophoresis device and method of using the same | |
| US20250010072A1 (en) | System and method for a micro stimulation device for ocular treatment | |
| CN203677369U (en) | Health eye patch | |
| WO2007050645A2 (en) | Intraocular iontophoretic device and associated methods | |
| CN215839869U (en) | Hydrogel eye patch for eye care of general anesthesia deep coma operation patient | |
| CN216962782U (en) | Multifunctional traditional Chinese medicine physiotherapy patch and physiotherapy instrument | |
| Dehghan et al. | Advances in iontophoresis for drug delivery | |
| KR101381977B1 (en) | Glasses for micro current stimulation | |
| CN2288718Y (en) | Medicine supply cleaning therapentic equipment for ophthalmopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140101 Termination date: 20150530 |
|
| EXPY | Termination of patent right or utility model |